ECOG EA7222 Doxo + pembro vs Doxorubicin for undifferentiated pleomorphic and related sarcomas

ECOG EA7222 Doxo + pembro vs Doxorubicin for undifferentiated pleomorphic and related sarcomas

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to find out if a drug called pembrolizumab (the study drug) is a safe and effective option for people with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. We want to know if adding it to treatment with the usual drug for this type of cancer can improve results.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Are diagnosed with UPS or a related poorly differentiated sarcoma
  • Have disease that is metastatic or unresectable
For more information about who can join this study, contact the study team at marty.c.cauley@duke.edu.

What is Involved?

Description

If you choose to join this study, you will get a random assignment (like a coin flip) to 1 of 2 arms in the study:
  • Arm A: If you are in this arm, you will take the study drug along with the standard drug (doxorubicin) used to treat this type of cancer.
  • Arm B: If you are in this arm, you will take the standard drug used to treat this type of cancer.

Study Details

Full Title

EA7222: A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

Principal Investigator

Richard
Riedel

Protocol Number

PRO00116156

NCT ID

NCT06422806

Phase

III

Enrollment Status

Open to Enrollment
ClinicalTrials.gov